Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Basel, June 1, 2026 – Novartis today announced positive 144-week data from the pivotal ASC4FIRST trial of Scemblix® (asciminib) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. These results provide longer-term evidence that Scemblix demonstrated increasingly superior molecular responses at week 144 compared with established tyrosine kinase inhibitors (TKIs), strengthening confidence in its sustained response1.
Basel, June 1, 2026 – Novartis today announced positive 144-week data from the pivotal ASC4FIRST trial of Scemblix® (asciminib) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. These results provide longer-term evidence that Scemblix demonstrated increasingly superior molecular responses at week 144 compared with established tyrosine kinase inhibitors (TKIs), strengthening confidence in its sustained response1.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.